Why did SPL fall 5.4% on 12 Aug 2026?

Starpharma launched a $32 million capital raise, causing dilution and a sharp drop in the stock price.

The substantial volume and price drop align with a capital raise announcement, which is dilutive to existing shareholders. Multiple articles confirm the $32M raise was announced around the event date, and the subsequent director purchases via entitlement offer corroborate the capital raise mechanism.

Written by a language model from the evidence below, and it can be wrong. Tell us and we will fix or remove it. General information only, not financial product advice.